Phase III Clinical Trial Designs Incorporating Predictive Biomarkers: An Overview

Shigeyuki Matsui ()
Additional contact information
Shigeyuki Matsui: Nagoya University Graduate School of Medicine, Department of Biostatistics

A chapter in Frontiers of Biostatistical Methods and Applications in Clinical Oncology, 2017, pp 85-103 from Springer

Abstract: Abstract Advances in biotechnology have revolutionized clinical trials in oncology, shifting the emphasis to co-developmentCo-development of molecularly targeted drugsMolecularly targeted drug and companion predictive biomarkers. However, the difficulty in developing and validating biomarkers in the early phases of clinical development complicates the design and analysis of definitive phase III trialsPhase III trial that aim to establish the clinical utilityClinical utility of new treatments with the aid of predictive markers. This chapter provides an overview of several designs for phase III trials that incorporate predictive markers at various levels of development and credibility, the latter in terms of these markers’ abilities to predict treatment responsiveness at the initiation of phase III trials. We first discuss the enrichment design and marker-stratifiedMarker-stratified all-comers designs with a single binary marker. For the marker-stratified designs, multi-stageMulti-stage analyses for sequential testing across the subgroupsSubgroup and adaptive subgroup selection are provided. We also discuss other adaptive designs, including the adaptive thresholdThreshold design and the adaptive signature design with some variants, in cases where the threshold for marker positivity is unclear or a single marker for use in evaluating treatment efficacy is not available at the initiation of phase III trials. Lastly, we introduce the prospective-Retrospective retrospective approachProspective-retrospective approach that allows for the evaluation of treatment efficacy in a marker subgroupSubgroup based on external evidence.

Keywords: Clinical trial designs; Phase III trials; Predictive biomarkers; Genomic signatures (search for similar items in EconPapers)
Date: 2017
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-981-10-0126-0_7

Ordering information: This item can be ordered from
http://www.springer.com/9789811001260

DOI: 10.1007/978-981-10-0126-0_7

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().